1. Sud01h is very much in the episodic treatment space as compared to the preventative treatment one. The new molecules target different pathways than the serotonin receptor agonist characteristic of sumatriptan. The seem to have pretty good efficacy too but are all compared to a placebo in clinical trials. I wonder why they aren't compared to the current standard of care (sumatriptan) rather than placebo? I expect only Sth would be able of answering that one.
2. Oromist IP is applicable to all of these new drugs as well i suspect in the event that the companies want to pursue a product extension path.
Thanks for the post.
SUD Price at posting:
0.6¢ Sentiment: Hold Disclosure: Held
